ClinicalTrials.gg
CompletedNCT00764634Updated Dec 2, 2011

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

A Phase 2 interventional study of Placebo (USP sterile saline for injection) and rBV A/B-40 vaccine in Botulism Vaccine, sponsored by DynPort Vaccine Company LLC, A GDIT Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-02.

Sponsored by DynPort Vaccine Company LLC, A GDIT Company · Phase 2 and Interventional

Phase
Phase 2
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.

Read the detailed description

The study includes 18 months (547 days) of follow-up after the first vaccination for all randomized volunteers who receive at least one vaccination. Analysis of cumulative data collected through Day 547 ± 14 days will be reported in the final clinical study report.

02

Conditions studied

  • Botulism Vaccine

Browse trials for

03

In context

Botulism

20 studies on the registry are indexed under Botulism; 3 are open to participants now.

This study's enrollment of 440 is above the median of 29 across 14 interventional studies indexed under Botulism.

Browse Botulism studies →

Lead sponsor

DynPort Vaccine Company LLC, A GDIT Company is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The volunteer has signed the form.
  2. The volunteer is 18 to 55 years of age.
  3. The volunteer agrees not to donate blood or blood product for therapeutic or research purposes.
  4. The volunteer is willing to comply with the requirements of the protocol.
  5. The volunteer has no abnormalities on .
  6. Female volunteers of must not be pregnant or lactating and agree to use two types of an acceptable form of FDA-approved through Day 365 ± 7 days.
  7. The volunteer is in good health.
  8. The volunteer has clinical laboratory test results within the ranges listed in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. The volunteer has a history of botulism or prior receipt of any botulinum vaccine, toxoid or antitoxin.
  2. The volunteer has previously been treated or expects to be treated with any therapeutic products containing BoNTs such as Botox®, Myobloc®/Neurobloc™ and Botox® Cosmetic.
  3. The volunteer has a history of or significant adverse reaction to other vaccines, aluminum compounds or yeast.
  4. The volunteer has donated one or more units of blood or undergone plasmapheresis within the past 28 days.
  5. The volunteer received any blood product or immunoglobulin in the previous 6 months.
  6. The volunteer received any vaccine in the previous 6 months.
  7. The volunteer received any licensed nonliving vaccine within 14 days before or after a scheduled vaccination.
  8. The volunteer received any licensed within 60 days before or after a scheduled vaccination.
  9. The volunteer received any investigational drug therapy within 30 days before the first vaccination or before the last scheduled visit.
  10. The volunteer received therapy with agents, including use of moderate to high-dose oral inhaled or systemic (prednisone-equivalent dose of ≥ 20 mg/day).
  11. The volunteer had neurological conditions associated with spasticity or abnormal muscle contraction, demyelination, other abnormalities of smooth or skeletal muscle function, migraine headache, or hyperhidrosis.
  12. The volunteer had systemic or recurrent disease or condition that would place the volunteer at an unacceptable risk of injury or requires frequent or continuous medical intervention for treatment, has required hospitalization, or is likely to require surgical intervention during the course of the study.
  13. The volunteer has a history of immunodeficiency or disease.
  14. The volunteer has a systemic medical condition that is ongoing or has required hospitalization or administration of antimicrobial agents within 6 months before screening.
  15. The volunteer has a history of arthritis on more than one occasion not related to trauma or any episode of non-trauma-related arthritis within the previous 6 months.
  16. The volunteer has an acute self-limited illness that has not resolved by the time of first vaccination including oral temperature greater than 99.5 °F.
  17. The volunteer has a history of abuse of alcohol or drugs within the 12 months before study screening.
  18. The volunteer has occupational or other responsibilities that would prevent completion of participation in the study.
  19. The volunteer has a ≥ 35 kg/m2.
  20. The volunteer has a confirmed positive result on a urine drug screen that tests for common substances of abuse such as amphetamines, barbiturates, benzodiazepines, cocaine, opiates and cannabinoids.
  21. The volunteer was seropositive on screening tests for , virus or surface antigen.
  22. The volunteer is currently on active duty in the U.S. military.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
440 participants (actual)

Study arms

  • Placebo comparator
    1 Placebo

    Biological: Placebo (USP sterile saline for injection)

  • Active comparator
    2 rBV A/B Vaccine

    Biological: rBV A/B-40 vaccine

  • Placebo comparator
    3 Placebo

    Biological: Placebo (USP sterile saline for injection)

  • Active comparator
    4 rBV A/B Vaccine

    Biological: rBV A/B-40 vaccine

Interventions

  • BiologicalPlacebo (USP sterile saline for injection)

    0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182

    Also known as: placebo

  • BiologicalrBV A/B-40 vaccine

    0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182

  • BiologicalPlacebo (USP sterile saline for injection)

    0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182

    Also known as: placebo

  • BiologicalrBV A/B-40 vaccine

    0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182

    Also known as: rBV A/B vaccine

06

What researchers measure

Primary outcomes

  1. The primary safety objective is to assess rBV A/B-40 vaccine or placebo given to volunteers with an observation period of 30 weeks (Day 210 ± 7 days). The primary immunogenicity objective is to evaluate neutralizing antibody rate.

    Time frame: 30 weeks (Day 210 ± 7 days)

Secondary outcomes

  1. The secondary safety objective is to assess rBV A/B-40 vaccine or placebo given to volunteers with an observation period of 18 months (Day 547 ± 14 days). The secondary immunogenicity objectives include evaluating antibody kinetics.

    Time frame: 18 months (Day 547 ± 14 days)

07

Study locations

6 sites
  • Miami Research Associates
    Miami, Florida 33143, United States
  • University Clinical Research, Inc
    Pembroke Pines, Florida 33024, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Clinical Research Associates of Tidewater
    Norfolk, Virginia 23507, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Mar 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2008
First posted
Oct 2, 2008
Start
Sep 2008
Primary completionActual
Mar 2010
CompletionActual
Dec 2010
Results delay requested
Jun 29, 2011
Last update
Dec 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00764634
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Responsible party
Sponsor
First posted
Oct 2, 2008
Start date
Sep 2008
Primary completion
Mar 2010
Completion
Dec 2010
Last update
Dec 2, 2011

Study contacts

William Swiderski
study director · DynPort Vaccine Company LLC
George A. Saviolakis, M.D.
study director · DynPort Vaccine Company LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion